دورية أكاديمية
Relationship between Th17 immune response and cancer.
| العنوان: | Relationship between Th17 immune response and cancer. |
|---|---|
| المؤلفون: | Marques HS; Campus Vitória da Conquista, Universidade Estadual do Sudoeste da Bahia, Vitória da Conquista 45083-900, Bahia, Brazil., de Brito BB; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., da Silva FAF; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., Santos MLC; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., de Souza JCB; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., Correia TML; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., Lopes LW; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., Neres NSM; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., Dórea RSDM; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., Dantas ACS; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., Morbeck LLB; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., Lima IS; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., de Almeida AA; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., Dias MRJ; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil., de Melo FF; Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil. freiremelo@yahoo.com.br. |
| المصدر: | World journal of clinical oncology [World J Clin Oncol] 2021 Oct 24; Vol. 12 (10), pp. 845-867. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101549149 Publication Model: Print Cited Medium: Print ISSN: 2218-4333 (Print) Linking ISSN: 22184333 NLM ISO Abbreviation: World J Clin Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014-: Pleasanton, CA : Baishideng Publishing Group Original Publication: Hong Kong : Baishideng Publishing Group |
| مستخلص: | Cancer is the second leading cause of death worldwide and epidemiological projections predict growing cancer mortality rates in the next decades. Cancer has a close relationship with the immune system and, although Th17 cells are known to play roles in the immune response against microorganisms and in autoimmunity, studies have emphasized their roles in cancer pathogenesis. The Th17 immune response profile is involved in several types of cancer including urogenital, respiratory, gastrointestinal, and skin cancers. This type of immune response exerts pro and antitumor functions through several mechanisms, depending on the context of each tumor, including the protumor angiogenesis and exhaustion of T cells and the antitumor recruitment of T cells and neutrophils to the tumor microenvironment. Among other factors, the paradoxical behavior of Th17 cells in this setting has been attributed to its plasticity potential, which makes possible their conversion into other types of T cells such as Th17/Treg and Th17/Th1 cells. Interleukin (IL)-17 stands out among Th17-related cytokines since it modulates pathways and interacts with other cell profiles in the tumor microenvironment, which allow Th17 cells to prevail in tumors. Moreover, the IL-17 is able to mediate pro and antitumor processes that influence the development and progression of various cancers, being associated with variable clinical outcomes. The understanding of the relationship between the Th17 immune response and cancer as well as the singularities of carcinogenic processes in each type of tumor is crucial for the identification of new therapeutic targets. Competing Interests: Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript. (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | N Engl J Med. 2009 Aug 27;361(9):888-98. (PMID: 19710487) Oncotarget. 2017 Jul 25;8(30):49757-49772. (PMID: 28537908) Leuk Lymphoma. 2019 Dec;60(14):3395-3405. (PMID: 31304817) J Immunol. 2000 Nov 15;165(10):5814-21. (PMID: 11067941) Cell. 2015 Sep 10;162(6):1229-41. (PMID: 26321679) Nature. 2006 May 11;441(7090):235-8. (PMID: 16648838) Immunity. 2011 Jan 28;34(1):108-21. (PMID: 21215658) J Immunother Cancer. 2020 Oct;8(2):. (PMID: 33093158) Angiogenesis. 2019 May;22(2):311-323. (PMID: 30539314) Int J Clin Exp Pathol. 2015 May 01;8(5):5702-8. (PMID: 26191284) Front Oncol. 2013 Jan 10;2:202. (PMID: 23336100) Arch Pharm Res. 2019 Jul;42(7):549-559. (PMID: 30941641) Int J Mol Sci. 2011;12(11):7424-37. (PMID: 22174607) Hum Immunol. 2012 Nov;73(11):1068-72. (PMID: 22863447) Am J Pathol. 2010 Aug;177(2):792-802. (PMID: 20595635) Oncogene. 2000 May 15;19(21):2548-56. (PMID: 10851053) Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):. (PMID: 28620097) Cancer Immunol Immunother. 2011 Oct;60(10):1473-84. (PMID: 21660450) J Exp Med. 2011 Oct 24;208(11):2321-33. (PMID: 22006976) Nat Immunol. 2011 Mar;12(3):255-63. (PMID: 21278737) J Exp Med. 2009 Jul 6;206(7):1457-64. (PMID: 19564351) J Clin Invest. 2006 May;116(5):1218-22. (PMID: 16670765) Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842) J Epidemiol Glob Health. 2019 Dec;9(4):217-222. (PMID: 31854162) Science. 2006 Sep 29;313(5795):1960-4. (PMID: 17008531) Cancer Immunol Res. 2018 Dec;6(12):1578-1592. (PMID: 30396909) Biomed Pharmacother. 2017 Apr;88:795-803. (PMID: 28160754) Science. 2004 Feb 13;303(5660):1007-10. (PMID: 14963329) Blood. 2009 Jun 11;113(24):6102-11. (PMID: 19366986) Front Immunol. 2019 Feb 04;10:115. (PMID: 30778354) Am J Clin Exp Urol. 2019 Aug 25;7(4):249-261. (PMID: 31511831) Prostate. 2012 Jan;72(1):90-9. (PMID: 21538420) Biomarkers. 2014 Jun;19(4):287-90. (PMID: 24731052) Cancer Immunol Res. 2018 Jul;6(7):788-797. (PMID: 29764837) Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5664-9. (PMID: 24706787) J Thorac Oncol. 2012 Jul;7(7):1091-100. (PMID: 22534817) Br J Haematol. 2020 Aug;190(4):e258-e261. (PMID: 32525232) Cell. 2010 Mar 19;140(6):845-58. (PMID: 20303875) J Exp Med. 2015 Mar 9;212(3):333-49. (PMID: 25732306) Science. 2009 Nov 13;326(5955):986-91. (PMID: 19797626) Nat Commun. 2017 Mar 14;8:14649. (PMID: 28290453) J Autoimmun. 2018 Feb;87:50-60. (PMID: 29371049) Cell Immunol. 2017 Dec;322:15-25. (PMID: 29103586) J Thorac Oncol. 2017 Aug;12(8):1268-1279. (PMID: 28483607) Biomarkers. 2015;20(4):232-9. (PMID: 26301881) Mol Immunol. 2021 Apr;132:199-208. (PMID: 33454107) Immunity. 2009 Jan 16;30(1):92-107. (PMID: 19119024) In Vivo. 2014 Nov-Dec;28(6):1005-11. (PMID: 25398793) Pancreas. 2017 Jan;46(1):19-27. (PMID: 27841793) J Biol Chem. 2012 Oct 12;287(42):35484-35495. (PMID: 22893706) Int J Mol Sci. 2017 Jun 20;18(6):. (PMID: 28632155) Eur J Immunol. 2011 Apr;41(4):936-51. (PMID: 21381020) J Immunol. 2009 May 1;182(9):5748-56. (PMID: 19380822) Blood. 2006 Aug 1;108(3):804-11. (PMID: 16861339) Stem Cells. 2006 Dec;24(12):2603-10. (PMID: 16931775) J Immunol. 2006 Oct 15;177(8):5377-85. (PMID: 17015723) Postepy Dermatol Alergol. 2014 Aug;31(4):256-61. (PMID: 25254011) Clin Cancer Res. 2009 May 15;15(10):3325-32. (PMID: 19417016) Immunol Lett. 2019 Sep;213:9-20. (PMID: 31278971) Cancer Res. 2004 Aug 15;64(16):5535-8. (PMID: 15313886) J Immunol. 1995 Dec 15;155(12):5483-6. (PMID: 7499828) Oncology (Williston Park). 2002 Feb;16(2):217-26, 229; discussion 230-2. (PMID: 11866137) Annu Rev Immunol. 2015;33:747-85. (PMID: 25706098) Viruses. 2017 Oct 19;9(10):. (PMID: 29048384) Immunity. 2011 Dec 23;35(6):972-85. (PMID: 22177921) Carcinogenesis. 2011 May;32(5):643-9. (PMID: 21304053) Gynecol Oncol. 2008 Mar;108(3):619-26. (PMID: 18222534) Cancer Biother Radiopharm. 2013 Jul-Aug;28(6):429-32. (PMID: 23701420) Cancer Lett. 2020 Oct 10;490:174-185. (PMID: 32721551) Kidney Int. 2010 Nov;78(9):838-48. (PMID: 20703216) Cytokine Growth Factor Rev. 2012 Dec;23(6):315-22. (PMID: 23022528) Epigenetics. 2014 Nov;9(11):1461-72. (PMID: 25470663) PLoS One. 2013;8(1):e53131. (PMID: 23372655) Cytokine. 2019 Jun;118:8-18. (PMID: 29396054) Histopathology. 2012 Jan;60(1):199-215. (PMID: 22212087) Eur J Immunol. 2015 Mar;45(3):922-31. (PMID: 25487261) Oncotarget. 2014 Oct 30;5(20):9530-1. (PMID: 25393980) Cancer Res. 2014 Apr 1;74(7):1969-82. (PMID: 24525743) Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10. (PMID: 18832156) Med Oncol. 2012 Dec;29(5):3024-8. (PMID: 22744708) Lancet. 2020 Jun 27;395(10242):2008-2020. (PMID: 32593337) Nature. 2012 Nov 8;491(7423):259-63. (PMID: 23075849) Nat Rev Immunol. 2007 Jan;7(1):41-51. (PMID: 17186030) J Exp Med. 2013 Dec 16;210(13):2851-72. (PMID: 24323355) Cancer Res. 2010 Dec 15;70(24):10112-20. (PMID: 21159633) Helicobacter. 2020 Feb;25(1):e12667. (PMID: 31702083) Biochem Biophys Res Commun. 2001 Apr 6;282(3):735-8. (PMID: 11401524) Curr Opin HIV AIDS. 2019 Mar;14(2):85-92. (PMID: 30543544) PLoS One. 2011 Apr 29;6(4):e19495. (PMID: 21559338) CA Cancer J Clin. 2017 May 6;67(3):177-193. (PMID: 28248415) Drug Intell Clin Pharm. 1987 Jun;21(6):487-92. (PMID: 3301244) Blood. 2009 Aug 6;114(6):1141-9. (PMID: 19470694) J Immunol. 2011 Apr 1;186(7):4388-95. (PMID: 21357259) Front Immunol. 2019 Feb 08;10:187. (PMID: 30800130) J Cancer. 2013;4(1):36-44. (PMID: 23386903) Head Neck Pathol. 2010 Dec;4(4):295-9. (PMID: 20697851) Cytokine Growth Factor Rev. 2011 Apr;22(2):83-9. (PMID: 21377916) Blood. 2010 Jul 1;115(26):5385-92. (PMID: 20395418) PLoS One. 2012;7(2):e32126. (PMID: 22359662) Immunity. 2008 Jan;28(1):29-39. (PMID: 18164222) J Clin Pathol. 2015 Jul;68(7):506-10. (PMID: 25750267) Am J Pathol. 2020 Jan;190(1):222-233. (PMID: 31654638) Zhonghua Zhong Liu Za Zhi. 2015 Jan;37(1):5-10. (PMID: 25877311) Annu Rev Immunol. 2011;29:235-71. (PMID: 21219185) Eur J Immunol. 2017 Apr;47(4):607-614. (PMID: 28295238) Oncol Lett. 2018 Nov;16(5):6215-6227. (PMID: 30405758) J Exp Med. 2010 Sep 27;207(10):2175-86. (PMID: 20819923) Cancer Res. 2009 Apr 1;69(7):3069-76. (PMID: 19318584) Immunity. 2008 Oct 17;29(4):628-36. (PMID: 18848474) J Immunol. 2009 Aug 1;183(3):1892-9. (PMID: 19596995) Blood Adv. 2017 Jul 21;1(17):1324-1334. (PMID: 29296775) Nat Commun. 2020 Oct 14;11(1):5173. (PMID: 33057068) Int J Clin Oncol. 2016 Jun;21(3):462-73. (PMID: 26899259) Pathol Oncol Res. 2015 Jan;21(1):139-46. (PMID: 24859972) J Immunol. 2005 Nov 1;175(9):6177-89. (PMID: 16237115) Eur J Cancer Prev. 2017 Jan;26(1):55-62. (PMID: 26731563) Blood. 2008 Sep 15;112(6):2340-52. (PMID: 18617638) Lancet. 2001 Feb 17;357(9255):539-45. (PMID: 11229684) Curr Opin HIV AIDS. 2010 Mar;5(2):114-9. (PMID: 20543587) J Exp Clin Cancer Res. 2013 Jan 11;32:3. (PMID: 23305119) Eur J Immunol. 2009 Jan;39(1):207-15. (PMID: 19130583) Immunol Res. 2014 Jan;58(1):118-24. (PMID: 24402773) BMC Med. 2015 Aug 24;13:202. (PMID: 26300242) J Int Med Res. 2020 Jun;48(6):300060520925948. (PMID: 32600079) J Cancer Stem Cell Res. 2014 May 29;2014(2):. (PMID: 25705705) Respir Med. 2018 Oct;143:129-138. (PMID: 30261984) Cell. 2019 Nov 14;179(5):1177-1190.e13. (PMID: 31730856) Nat Immunol. 2007 Apr;8(4):345-50. (PMID: 17375096) J Leukoc Biol. 2011 Jan;89(1):85-91. (PMID: 20952660) Front Immunol. 2017 Mar 31;8:254. (PMID: 28408906) Cancer Immunol Immunother. 2015 Sep;64(9):1185-91. (PMID: 26047578) J Autoimmun. 2018 Feb;87:1-15. (PMID: 29275836) Cancer Immunol Res. 2018 Jun;6(6):645-657. (PMID: 29653981) Keio J Med. 2003 Sep;52(3):147-50. (PMID: 14529146) J Immunol. 2008 Jan 1;180(1):214-21. (PMID: 18097022) Mediators Inflamm. 2015;2015:802939. (PMID: 25969628) Front Immunol. 2019 Jul 18;10:1690. (PMID: 31379875) Front Immunol. 2014 Jun 17;5:276. (PMID: 24987392) Mediators Inflamm. 2013;2013:713859. (PMID: 24453427) Sci Rep. 2013 Dec 09;3:3456. (PMID: 24316750) Cell Stem Cell. 2015 Mar 5;16(3):225-38. (PMID: 25748930) Int J Cancer. 2016 Aug 15;139(4):869-81. (PMID: 27062572) Turk J Gastroenterol. 2018 Jan;29(1):45-51. (PMID: 29391307) Lancet. 2020 Aug 29;396(10251):635-648. (PMID: 32861308) Eur Rev Med Pharmacol Sci. 2014;18(18):2720-86. (PMID: 25317809) Oncoimmunology. 2015 Feb 03;4(1):e984539. (PMID: 25949866) Mol Cancer. 2011 Dec 15;10:150. (PMID: 22171994) Blood. 2011 Nov 10;118(19):5084-95. (PMID: 21881045) Res Rep Urol. 2020 Nov 30;12:593-597. (PMID: 33299822) Biomed Res Int. 2015;2015:314620. (PMID: 26583099) World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. (PMID: 30487695) Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):7061-6. (PMID: 26038559) Medicine (Baltimore). 2020 Dec 4;99(49):e23145. (PMID: 33285688) J Clin Invest. 2009 Mar;119(3):565-72. (PMID: 19188681) Cancer Res. 2005 Jan 15;65(2):465-72. (PMID: 15695388) Nature. 2017 Jan 18;541(7637):321-330. (PMID: 28102259) Cancer Res. 2012 May 15;72(10):2589-99. (PMID: 22461511) J Exp Med. 2020 Dec 7;217(12):. (PMID: 32860704) N Engl J Med. 2011 Sep 22;365(12):1118-27. (PMID: 21992124) Med Sci Monit. 2018 Nov 01;24:7802-7808. (PMID: 30381753) Emerg Microbes Infect. 2013 Sep;2(9):e60. (PMID: 26038490) Cancer. 2017 Jul 1;123(13):2404-2412. (PMID: 28464289) PLoS One. 2017 Aug 22;12(8):e0183415. (PMID: 28829805) Int Immunopharmacol. 2018 Mar;56:320-329. (PMID: 29438938) Oncoimmunology. 2015 Mar 06;4(2):e984547. (PMID: 25949881) Int J Clin Exp Pathol. 2019 Sep 01;12(9):3604-3612. (PMID: 31934210) Nat Commun. 2011 Dec 20;2:600. (PMID: 22186896) Immunity. 2008 Apr;28(4):454-67. (PMID: 18400188) PLoS One. 2016 Jan 26;11(1):e0148044. (PMID: 26812681) Arthritis Res Ther. 2008;10(2):206. (PMID: 18466633) Cancer Res. 2015 Nov 15;75(22):4852-62. (PMID: 26404002) Oncoimmunology. 2017 Sep 21;7(1):e1373234. (PMID: 29296528) Cells. 2020 Jul 10;9(7):. (PMID: 32664207) BMC Womens Health. 2020 Jun 17;20(1):126. (PMID: 32552719) Blood. 2009 Aug 6;114(6):1134-5. (PMID: 19661273) PLoS One. 2015 Mar 13;10(3):e0120855. (PMID: 25768730) PLoS One. 2011;6(9):e24856. (PMID: 21949768) Clin Exp Med. 2019 Aug;19(3):385-391. (PMID: 31102004) PLoS One. 2012;7(2):e30676. (PMID: 22363469) Future Oncol. 2018 Apr;14(10):907-917. (PMID: 29260582) Leukemia. 2013 Jul;27(7):1527-37. (PMID: 23399894) Ginekol Pol. 2012 Apr;83(4):295-300. (PMID: 22712263) Nature. 2011 May 19;473(7347):337-42. (PMID: 21593866) Cytokine. 2017 Jan;89:34-44. (PMID: 26883678) Crit Rev Oncol Hematol. 2020 Jun;150:102945. (PMID: 32353704) Nature. 2015 Jul 9;523(7559):221-5. (PMID: 25924064) Prostate. 2017 Jun;77(8):888-899. (PMID: 28240383) Cytokine. 2019 Apr;116:7-12. (PMID: 30684916) Blood. 2002 Mar 15;99(6):2114-21. (PMID: 11877287) Immunology. 2011 Oct;134(2):214-23. (PMID: 21896015) Immunotherapy. 2019 Feb;11(2):69-74. (PMID: 30727800) Nat Immunol. 2013 Oct;14(10):1014-22. (PMID: 24048123) Nature. 2013 Apr 25;496(7446):518-22. (PMID: 23467095) Microb Pathog. 2015 Apr;81:33-8. (PMID: 25773771) Scand J Immunol. 2011 Jul;74(1):47-51. (PMID: 21352252) Cancer Res. 2009 Jul 1;69(13):5522-30. (PMID: 19509224) J Immunol. 2011 Mar 15;186(6):3462-71. (PMID: 21300825) J Allergy Clin Immunol. 2010 Jan;125(1):222-30.e1-4. (PMID: 20109749) Blood. 2010 Jan 14;115(2):335-43. (PMID: 19890092) Mod Pathol. 2018 Jul;31(7):1012-1025. (PMID: 29463884) J Immunol. 2010 Feb 1;184(3):1630-41. (PMID: 20026736) PLoS One. 2017 Sep 21;12(9):e0185168. (PMID: 28934305) J Oncol. 2020 Feb 21;2020:8797683. (PMID: 32148497) |
| فهرسة مساهمة: | Keywords: Cancer; Immune response; Interleukin-17; Pathophysiology; Th17 cells; Tumor microenvironment |
| تواريخ الأحداث: | Date Created: 20211104 Latest Revision: 20231108 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8546660 |
| DOI: | 10.5306/wjco.v12.i10.845 |
| PMID: | 34733609 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!